Niraparib interactions
Full monograph for NiraparibCheck it against another medicine
Medicines
203 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 2 sources — open the full entry |
| Rotavirus Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 9 sources — open the full entry |
| Tofacitinib | Major | Others | Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 1 sources — open the full entry |
| Upadacitinib | Major | Others | Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Yellow Fever Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Abemaciclib | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Acalabrutinib | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Aflibercept | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Allium cepa + Heparin + Allantoin | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 2 sources — open the full entry |
| Alpelisib | Moderate | Others | Coadministration of inhibitors of the breast cancer resistance protein (BCRP) transporter with alpelisib may increase the plasma concentrations and risk of… | 3 sources — open the full entry |
| Alteplase | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 2 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Absorption | Coadministration with potent inhibitors of P-glycoprotein (P-gp) may increase the bioavailability of niraparib, which is a substrate of the efflux transporter… | 1 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Apixaban | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 2 sources — open the full entry |
| Asciminib | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. | 1 sources — open the full entry |
| Aspirin | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 2 sources — open the full entry |
| Aspirin + Dipyridamole | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.2 documented mechanisms | 2 sources — open the full entry |
| Azacitidine | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Azathioprine | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections… | 3 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Bendamustine | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Betrixaban | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 2 sources — open the full entry |
| Bivalirudin | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 2 sources — open the full entry |
| Bleomycin Sulfate | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Bortezomib | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Bromfenac Sodium | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 2 sources — open the full entry |
| Cabazitaxel | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Cabozantinib | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 2 sources — open the full entry |
| Capecitabine | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Capmatinib Hydrochloride | Moderate | Absorption | Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)… | 1 sources — open the full entry |
| Carbamazepine | Moderate | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may decrease the bioavailability of niraparib, a substrate of the efflux transporter, which may… | 2 sources — open the full entry |
| Carboplatin | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Carfilzomib | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Carmustine | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Ceritinib | Moderate | Excretion | Coadministration with ceritinib may increase the plasma concentrations and the risk of adverse effects of orally administered drugs that are substrates of the… | 2 sources — open the full entry |
| Chlorambucil | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Chloramphenicol (Ophthalmic) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Cilostazol | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 2 sources — open the full entry |
| Cisplatin | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Clopidogrel + Aspirin | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.2 documented mechanisms | 2 sources — open the full entry |
| Clopidogrel Bisulphate | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 2 sources — open the full entry |
Conditions
Conditions in which Niraparib needs care, as documented in this source.
Cardiovascular disease
ModerateNiraparib has the potential to cause effects on pulse rate and blood pressure. Hypertension and hypertensive crisis have been reported in patients treated with niraparib. It is recommended to monitor blood pressure and heart rate monthly for the first year and periodically thereafter during treatment with niraparib. Closely monitor patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Medically manage hypertension with antihypertensive medications and adjust the dose of niraparib as necessary.
1 source
- "Product Information. Zejula (niraparib)." Tesaro Inc. (2017):
Kidney Diseases
ModerateNo dose adjustment is necessary for patients with mild to moderate renal impairment. Caution is recommended in patients with severe renal impairment or end stage renal disease undergoing hemodialysis as the safety of niraparib has not been established in these patients.
1 source
- "Product Information. Zejula (niraparib)." Tesaro Inc. (2017):
Liver Diseases
ModerateNo dose adjustment is needed in patients with mild hepatic impairment according to the National Cancer Institute - Organ Dysfunction Working Group (NCI-ODWG) criteria. Caution is recommended in patients with moderate to severe hepatic impairment as the safety of niraparib has not been established in these patients.
1 source
- "Product Information. Zejula (niraparib)." Tesaro Inc. (2017):
Myelodysplastic Syndromes
ModerateMyelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), including cases with fatal outcome, have been reported with the use of niraparib. It is recommended to use caution when using this agent in patients with MDS/AML, its use must be weighed against the risk. Discontinue the use of niraparib in patients who develop MDS/AML.
1 source
- "Product Information. Zejula (niraparib)." Tesaro Inc. (2017):
Pancytopenia
ModerateHematologic adverse reactions (thrombocytopenia, anemia and neutropenia) have been reported in patients treated with niraparib. It is recommended to monitor complete blood counts weekly for the first month, monthly for the next eleven months of treatment, and periodically after this time. Do not start niraparib until patients have recovered from hematological toxicity caused by previous chemotherapy (less than equal to Grade 1). If hematological toxicities do not resolve within 28 days following interruption, discontinue niraparib, and refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics.
1 source
- "Product Information. Zejula (niraparib)." Tesaro Inc. (2017):